What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2025-05-13 compared with 2024-11-13 · 320 added, 376 removed, 6 unchanged (99% of the section changed)

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

following discussion and analysis are intended to help prospective investors understand our business, financial condition, results of

operations, liquidity and capital resources.

You should read this discussion in conjunction with our condensed consolidated financial

statements and related notes thereto included elsewhere in this information statement.

statements in this discussion regarding industry outlook, expectations regarding our future performance, liquidity and capital resources

and other non-historical statements are forward-looking statements.

These forward-looking statements are subject to numerous risks and

uncertainties, including, but not limited to, the risks and uncertainties described in “Special Note Regarding Forward-Looking

Statements.” Actual results may differ materially from those contained in any forward-looking statements.

NexGel Financial Statements, discussed below, reflect the NexGel financial condition, results of operations, and cash flows.

The financial

information discussed below and included in this information statement, however, may not necessarily reflect what the NexGel financial

condition, results of operations, or cash flows would have been had NexGel been operated as a separate, independent entity during the

years presented, or what the NexGel financial condition, results of operations, and cash flows may be in the future.

Forward-Looking

Quarterly Report on Form 10-Q contains “forward-looking statements,” which include information relating to future events,

future financial performance, strategies, expectations, competitive environment and regulation.

Words such as “may,” “should,”

“could,” “would,” “predict,” “potential,” “continue,” “expect,”

“anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,”

and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should

not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will

actually be achieved.

Forward-looking statements are based on information we have when those statements are made or our management’s

good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance

or results to differ materially from those expressed in or suggested by the forward-looking statements.

Important factors that could

cause such differences include, but are not limited to:

ability to continue as a going concern;

or an inability to raise sufficient capital to execute our business plan;

ability to comply with current good manufacturing practices;

or retirement of key executives;

plans to make significant additional outlays of working capital before we expect to generate significant revenues and the uncertainty

regarding when we will begin to generate significant revenues, if we are able to do so;

economic conditions and/or intense competition;

of a key customer or supplier;

of new competitors;

federal, state and local government regulation;

technological

obsolescence of our manufacturing process and equipment;

problems with our research and products;

of mergers and acquisitions including the time and cost of implementing transactions and the potential failure to achieve expected

gains, revenue growth or expense savings;

increases for supplies and components;

inability to carry out our business plans.

a discussion of these and other risks that relate to our business and investing in shares of our common stock, you should carefully

review the risks and uncertainties described elsewhere in the Company’s Annual Report on Form 10-K filed with the SEC on April

The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified in their entirety

by this cautionary statement.

We do not undertake any obligation to publicly update any forward-looking statement to reflect events

or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

From 2019 through November 2023, we only

manufactured high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics,

transdermal drug delivery and cosmetics.

We specialize in custom gels by capitalizing on proprietary manufacturing technologies.

historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products.

in 2020, we created two new lines of business for the company.

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis are intended

to help prospective investors understand our business, financial condition, results of operations, liquidity and capital resources.

should read this discussion in conjunction with our condensed consolidated financial statements and related notes thereto included elsewhere

in this information statement.

The statements in this discussion regarding industry

outlook, expectations regarding our future performance, liquidity and capital resources and other non-historical statements are forward-looking

These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks

and uncertainties described in “Special Note Regarding Forward-Looking Statements.” Actual results may differ materially from

those contained in any forward-looking statements.

The NexGel Financial Statements, discussed below,

reflect the NexGel financial condition, results of operations, and cash flows.

The financial information discussed below and included

in this information statement, however, may not necessarily reflect what the NexGel financial condition, results of operations, or cash

flows would have been had NexGel been operated as a separate, independent entity during the years presented, or what the NexGel financial

condition, results of operations, and cash flows may be in the future.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking

statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive

environment and regulation.

Words such as “may,” “should,” “could,” “would,” “predict,”

“potential,” “continue,” “expect,” “anticipate,” “future,” “intend,”

“plan,” “believe,” “estimate,” and similar expressions, as well as statements in future tense, identify

forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results and may not

be accurate indications of when such performance or results will actually be achieved.

Forward-looking statements are based on information

we have when those statements are made or our management’s good faith belief as of that time with respect to future events and are

subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested

by the forward-looking statements.

Important factors that could cause such differences include, but are not limited to:

our ability to continue as a going concern;

inadequate capital;

inadequate or an inability to raise sufficient capital to execute our business plan;

our ability to comply with current good manufacturing practices;

loss or retirement of key executives;

our plans to make significant additional outlays of working capital before we expect to generate significant revenues and the uncertainty regarding when we will begin to generate significant revenues, if we are able to do so;

adverse economic conditions and/or intense competition;

loss of a key customer or supplier;

entry of new competitors;

adverse federal, state and local government regulation;

technological obsolescence of our manufacturing process and equipment;

technical problems with our research and products;

risks of mergers and acquisitions including the time and cost of implementing transactions and the potential failure to achieve expected gains, revenue growth or expense savings;

price increases for supplies and components;

the inability to carry out our business plans.

For a discussion of these and other risks that relate

to our business and investing in shares of our common stock, you should carefully review the risks and uncertainties described elsewhere

in this Quarterly Report on Form 10-Q.

The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified

in their entirety by this cautionary statement.

We do not undertake any obligation to publicly update any forward-looking statement to

reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

There may be other factors that may cause our actual

results to differ materially from the forward-looking statements, including factors disclosed under the section titled and “Management’s

Discussion and Analysis of Financial Condition and Results of Operations” in this information statement.

You should evaluate all

forward-looking statements made in this information statement in the context of these risks and uncertainties.

No assurance can be given that any goal or plan set

forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements

which speak only as of the date they are made.

We do not undertake any obligation to update or release any revisions to any forward-looking

statement or to report any events or circumstances after the date of this information statement or to reflect the occurrence of unanticipated

events, except as required by law.

We manufacture high water content, electron beam cross-linked,

aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics.

We specialize in

custom gels by capitalizing on proprietary manufacturing technologies.

We have historically served as a contract manufacturer, supplying

our gels to third parties who incorporate them into their own products.

Beginning in 2020, we created two new lines of business for the

First, our own line of branded consumer products sold direct to consumers.

Second, we expanded into custom and white label opportunities, which focuses on combining our gels with proprietary branded products

and white label opportunities.

All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking

technologies.

Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to

a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate [a

measure of the passage of water vapor through a substance] and release rate) while maintaining product integrity.

Additionally, we have

the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated.

Consequently, we and our

customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing

color and texture.

On March 1, 2023, the Company acquired a 50% interest

in a newly formed JV for its converting and packaging business.

The new JV expands the Company’s offerings, allowing it to reach

more customers with a variety of gel shapes and sizes.

The Company had limited converting and packaging operations in its Langhorne Facility,

making a JV to expand capacity an attractive opportunity.

in December 2023, the Company expanded their product portfolio to include the Kenkoderm brand.

Kenkoderm is a skincare line focused

on reducing symptoms associated with psoriasis.

Kenkoderm products do not utilize our gel technology and are manufactured by third

This marks the first time the company expanded its product portfolio to include products unrelated to its core gel

in May 2024, the Company added the Silly George brand.

Silly George is a beauty and cosmetics company focused on eyeliner, fake

eyelashes, lash serum and mascara.

Similar to Kenkoderm, Silly George products are purchased and resold from third party

manufacturers.

This second acquisition further expanded the Company’s retail sales presence in products unrelated to its core

gel technology.

March 1, 2023, the Company acquired a 50% interest in its newly formed JV for its converting and packaging business.

The JV agreement

is effective March 1, 2023.

As a result of this transaction, the Company owns 50% of the JV, with the remaining 50% held by CG Labs.

January 6, 2023, the Company acquired a 50% interest in its newly formed JV to pursue branded consumer product retail opportunities and

the development of new patch products.

The JV agreement is effective January 6, 2023.

As a result of this transaction, the Company owns

50% of the JV, with the remaining 50% held by Moiety.

December 1, 2023, we purchased substantially all of the assets of Olympus Trading Company, LLC (the “Kenkoderm Seller”) related

to the Seller’s skincare line focused on reducing symptoms associated with psoriasis operating under the tradename “Kenkoderm”

(“Kenkoderm acquisition”).

May 15, 2024, the Company purchased substantially all of the assets from Semmens Online Pty Ltd as Trustee for Semmens Business Trust

related to the SG Seller’s eyeliner, fake eyelashes, lash serum and mascara business operating under the tradename “Silly

of Operations

following sections discuss and analyze the changes in the significant line items in the accompanying condensed consolidated statements

of operations for the comparison periods identified.

of the Three Months ended September 30, 2024 and 2023 ($ in thousands)

the three months ended September 30, 2024 revenues were $2,940 and increased by $1,719, or 140.8%, when compared to $1,221 for the three

months ended September 30, 2023.

The increase in our overall revenues was primarily due to sales growth in our branded consumer products,

including gross revenue from Silly George of $1,373 for the three months ending September 30, 2024, and partially offset by a decrease

in contract manufacturing.

Company has four distinct lines of business;

Contract Manufacturing, Custom and White Label, Branded Consumer Products, and Medical Devices.

Manufacturing

order rolls of gel (“rollstock”).

Second, we expanded into custom and white label opportunities,

which focuses on combining our gels with proprietary branded products and white label opportunities.

All of our gel products are manufactured

using proprietary and non-proprietary mixing, coating and cross-linking technologies.

Together, these technologies enable us to produce

gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water

content, adherence, absorption, moisture vapor transmission rate [a measure of the passage of water vapor through a substance] and release

rate) while maintaining product integrity.

Additionally, we have the manufacturing ability to offer broad choices in the selection of

liners onto which the gels are coated.

Consequently, we and our customers are able to determine tolerances in moisture vapor transmission

rate and active ingredient release rates while personalizing color and texture.

In May 2023, we formed a joint venture with CG Laboratories,

called CG Converting and Packaging, LLC, which is located in Granbury, Texas and of which we own a 50% interest, allowing us to expand

our ability to deliver finished goods to our growing customer base.

We have four distinct lines of business;

Manufacturing, Custom & White Label, Consumer Branded Products, and Medical Devices/Other, which are described below.

Contract Manufacturing

Customers order rolls of gel (“rollstock”).

The rollstock is shipped to our customers, which they package into finished goods.

Historically,

this has been the Company’s primary source of revenue.

and White Label

products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g.

into the gel for a beauty mask).

The rollstock is converted and packaged into saleable units.

The finished goods are shipped to the customer,

who is ultimately responsible for product distribution.

Frequently these products started as development deals, in which the customer

paid the company a small fee to develop a specific product.

Once completed, the customer places a large order for newly developed product.

Consumer Products

products are finished goods marketed and sold directly to the customer by the Company through online and retail channels.

is responsible for sales, marketing, and distribution.

These products carry the Company’s brand names, which include Medagel, Lumagel

Beauty, Kenkoderm and Silly George.

Devices/Other

Devices are a hybrid business, combining elements of Custom and White Label and Branded Consumer Products.

Medical Devices, which are

not yet marketed, are expected to be distributed through strategic partnerships.

The Company will manufacture and possibly convert/package

the device while the strategic partner brings the product to market.

Small market Medical Devices could be launched by the Company, but

also be offered to a distributor to reach the full scale of the market.

includes freight charged to customers who purchase the Company’s branded consumer products through their Shopify stores.

Our gross profit was $1,282 thousand for the three months ended September 30, 2024 compared to a gross profit of $344 thousand

for the three months ended September 30, 2023.

The increase of $938 in gross profit quarter over quarter was primarily due to the increase

in branded consumer products.

Gross profit was 43.6% for the three months ended September 30, 2024 compared to a gross profit of 28.2%

for the three months ended September 30, 2023.

components of cost of revenues are as follows for the three months ended September 30, 2024 and 2023 ($ in thousands):

and finished products

and amortization

production and other expenses

Historically, this was the Company’s primary

source of revenue.

Custom & White Label

These products often infuse various ingredients

into our base gel to develop unique product offerings to satisfy market demand (e.g.

aloe infused into the gel for a beauty mask).

rollstock is converted and packaged into salable units.

The finished goods are shipped to the customer, who is ultimately responsible

for product distribution.

Frequently these products started as development deals, in which the customer paid the company a small fee to

develop a specific product.

Once completed, the customer places an order for newly developed product.

Consumer Branded Products

These products are finished goods marketed

and sold directly to consumers by the Company through online and retail channels.

We are responsible for sales, marketing, and distribution.

The products we sell under our MedaGel brand primarily relate to healthcare over-the-counter (“OTC”) remedy solutions, such

as blister and applications.

In December 2023 we added a second consumer product brand when we completed the purchase of the Kenkoderm

The Kenkoderm skincare line was originally developed by a dermatologist to provide gentle to the skin products for consumer with

In May 2024, we added our third consumer product brand with the purchase of the Silly George brand.

Silly George is a beauty

brand primarily focused on false eyelashes and other eye related products.

We continue to look for additional potential acquisitions as

part of our consumer product ‘roll-up” strategy.

Medical Devices/Other

Medical Devices are a hybrid business,

combining elements of Custom & White Label and Consumer Branded Products.

Medical Devices, which are not yet marketed, are expected

to be distributed through strategic partnerships.

We will manufacture and possibly convert/package the device while the strategic partner

brings the product to market.

Small market Medical Devices could be launched by us, but also be offered to a distributor to reach the

full scale of the market.

Other includes freight charged to customers

who purchase the Company’s branded consumer products through their Spotify stores.

Results of Operations

The following sections discuss and analyze the changes

in the significant line items in the accompanying condensed consolidated statements of operations for the comparison periods identified.

Comparison of the Three Months ended March 31,

2025 and 2024 ($ in thousands)

Revenues, net .

For the three months ended March 31, 2025 revenues

were $2,806 and increased by $1,540, or 121.6%, when compared to $1,266 for the three months ended March 31, 2024.

The increase in our

overall revenues was primarily due to sales growth in both our contract manufacturing and branded products.

Gross profit (loss) .

Our gross profit was $1,188

for the three months ended March 31, 2025 compared to a gross profit of $160 for the three months ended March 31, 2024.

The increase of

$1,028 in gross profit quarter over quarter was primarily due to the increase in consumer branded products.

Gross profit was 42.3% for

the three months ended March 31, 2025 compared to a gross profit of 12.6% for the three months ended March 31, 2024.

The components of cost of revenues are as follows

for the three months ended March 31, 2025 and 2024 ($ in thousands):

Three Months Ended

Cost of revenues

of revenues increased by $781, or 89.1%, to $1,658 for the three months ended September 30, 2024, as compared to $877 for the three months

ended September 30, 2023.

The increase in cost of revenues is primarily aligned with sales of branded consumer products, as both Silly

George and Kenkoderm were acquired after the comparable 2023 time period.

general and administrative expenses .

The following table highlights Selling, general and administrative expenses by type for the

three months ended September 30, 2024 and 2023 ($ in thousands):

general and administrative expenses

and amortization

marketing, and Amazon fees

and shareholder services

tax and corporate insurance

and consulting fees

expenses and professional fees

Materials and finished products

Share-based compensation

Compensation and benefits

Depreciation and amortization

Commission and contract fees

Equipment, production and other expenses

Total cost of revenues

Cost of revenues increased by $512, or 46.3%, to $1,618

for the three months ended March 31, 2025, as compared to $1,106 for the three months ended March 31, 2024.

The increase in cost of revenues

is primarily aligned with sales of branded consumer products, as Silly George was acquired after the comparable 2024 time period.

Selling, general and administrative expenses .

general and administrative expenses increased by $1,120, or 117.9%, to $2,070 for the three months ended September 30, 2024, as compared

to $950 for the three months ended September 30, 2023.

The increase in Selling, general and administrative expenses is primarily attributable

to the factors described below.

and benefits increased by $70, or 41.4%, to $239 for the three months ended September 30, 2024, as compared to $169 for the three months

ended September 30, 2023.

The number of employees increased compared to the prior period and officer compensation increased in conjunction

with contract renewals.

compensation increased by $77 or 116.7%, to $143 for the three months ended September 30, 2024, as compared to $66 for the three months

ended September 30, 2023.

The increase related to the issuance of stock options and restricted awards to our officers, employees, board

of directors, and advisors.

marketing, Amazon fees increased by $819, or 460.1%, to $997 for the three months ended September 30, 2024, as compared to $178 for the

three months ended September 30, 2023.

The increase is due to the increased Amazon selling fees and an increase in advertising and marketing

attributable to promoting Kenkoderm and Silly George.

and shareholder services decreased by $39 or 45.3%, to $47 for the three months ended September 30, 2024, as compared to $86 for the

three months ended September 30, 2023.

The decrease is due to a net reduction of investor services compared to the prior year period.

taxes and corporate insurance decreased by $14, or 26.9%, to $38 for the three months ended September 30, 2024, as compared to $52 thousand

for the three months ended September 30, 2023.

In the prior year period, a non-recurring adjustment resulted in an increase in franchise

and consulting fees increased by $104, or 38.4%, to $375 for the three months ended September 30, 2024, as compared to $271 for the three

months ended September 30, 2023.

We continued to incur accounting and consulting fees associated with public company governance requirements

and professional services related to branded consumer products.

Expenses increased by $81, or 65.9%, to $204 for the three months ended September 30, 2024 from $123 for the three months ended September

Other Selling, general and administrative expenses generally consist of normal costs associated with our selling efforts and

general management, including information technology, travel, training and recruiting.

and development expenses .

Research and development expenses decreased by $6, or 100%, to $0 for the three months ended September 30,

2024 from $6 for the three months ended September 30, 2023.

Research and development expenses are related to research costs incurred

for potential products for existing or new customers.

of the Nine Months ended September 30, 2024 and 2023 (in thousands)

the nine months ended September 30, 2024, revenues were $5,647 and increased by $2,640, or 87.8%, when compared to $3,007 for the nine

months ended September 30, 2023.

The increase in our overall revenues was primarily due to sales growth in our branded consumer products,

including gross revenue from Silly George of $1,753 from May 15, 2024 through September 30, 2024, and partially offset by a decrease

in contract manufacturing.

Our gross profit was $1,969 for the nine months ended September 30, 2024, compared to a gross profit of $461 for the nine

months ended September 30, 2023.

The increase of $1,508 in gross profit recorded for the nine months ended September 30, 2024, as compared

to the nine months ended September 30, 2023, was primarily due to increase in branded consumer products.

Gross profit was approximately

34.9% for the nine months ended September 30, 2024, compared to a gross profit of 15.3% for the nine months ended September 30, 2023.

components of cost of revenues are as follows for the nine months ended September 30, 2024 and 2023 ($ in thousands):

and finished products

based compensation

and amortization

production, and other expenses

cost of revenues

of revenues increased by $1,132, or 44.5%, to $3,678 for the nine months ended September 30, 2024, as compared to $2,546 for the nine

months ended September 30, 2023.

The increase in cost of revenues pertains to an increase in materials and finished products.

in cost of revenues is primarily aligned with sales of branded consumer products, as both Silly George and Kenkoderm were acquired after

the comparable 2023 time period.

general, and administrative expenses .

The following table highlights selling, general, and administrative expenses by type for the

nine months ended September 30, 2024 and 2023 ($ in thousands):

general, and administrative expenses

and amortization

marketing, and Amazon fees

and shareholder services

tax and corporate insurance

and consulting fees

The following table highlights Selling, general and administrative expenses by type for the three months ended March 31, 2025 and 2024

($ in thousands):

Three Months Ended

Selling, general and administrative expenses

general, and administrative expenses increased by $1,975 or 75.1%, to $4,604 for the nine months ended September 30, 2024, as compared

to $2,629 for the nine months ended September 30, 2023.

The increase in selling, general, and administrative expenses is primarily attributable

to increased Advertising, marketing and Amazon fees, which directly correlates to our growth in branded consumer products.

and benefits increased by $253, or 51.6%, to $743 for the nine months ended September 30, 2024, as compared to $490 for the nine months

ended September 30, 2023.

The number of employees increased compared to the prior period and officer compensation increased in conjunction

with contract renewals.

compensation increased by $137, or 125.7%, to $246 for the nine months ended September 30, 2024, as compared to $109 for the nine months

ended September 30, 2023.

The increase related to the issuance of stock options and restricted awards to our officers, employees, board

of directors, and advisors.

marketing, Amazon fees increased by $1,255 or 286.5%, to $1,693 for the nine months ended September 30, 2024, as compared to $438 for

the nine months ended September 30, 2023.

The increase is due to the increased Amazon selling fees and increase in advertising and marketing

attributable to promoting Kenkoderm and Silly George.

and shareholder services decreased by $126 or 39.0%, to $197 for the nine months ended September 30, 2024, compared to $323 for the nine

months ended September 30, 2023.

The decrease is due to a net reduction of investor services compared to the prior year period.

taxes and corporate insurance decreased by $56 or 32.2%, to $118 for the nine months ended September 30, 2024, as compared to $174 for

the nine months ended September 30, 2023.

In the prior year period, a non-recurring adjustment resulted in an increase in franchise taxes.

and consulting fees increased by $317 or 38.5% to $1,140 for the nine months ended September 30, 2024, as compared to $823 for the nine

months ended September 30, 2023.

We continued to incur accounting and consulting fees associated with public company governance requirements

and professional services related to branded consumer products.

expenses increased by $117, or 48.8%, to $357 for the nine months ended September 30, 2024 from $240 for the nine months ended September

Other Selling, general and administrative expenses generally consist of normal costs associated with our selling efforts and

general management, including information technology, travel, training and recruiting.

and development expenses .

Research and development expenses decreased by $12, or 13.3% to $78 for the nine months ended September

30, 2024 from $90 for the nine months ended September 30, 2023.

Research and development expenses are related to research costs incurred

for potential products for existing or new customers.

and Capital Resources

Flow (in thousands)

cash used in operating activities

cash provided by (used in) investing activities

cash provided by financing activities

increase (decrease) in cash and cash equivalents

and cash equivalents at beginning of year

and cash equivalent at end of quarter

of September 30, 2024, we had $1,059 of cash and cash equivalents, compared to $2,700 of cash and cash equivalents at December 31, 2023.

Net cash used in operating activities was $3,008 and $2,649 for the nine months ended September 30, 2024 and 2023, respectively.

cash used in investing activities was $712 and net cash provided by investing activities was $4,729 for the nine months ended September

30, 2024 and 2023, respectively, consisting of the sales of marketable securities of $62, the purchase of capital equipment of $374 and

the Silly George acquisition of $400 for nine months ended September 30, 2024 and consisting of the sales of marketable securities of

$5,340 and purchases of capital equipment of $611 for nine months ended September 30, 2023.

cash provided by financing activities for the nine months ended September 30, 2024 was $2,079 consisting of net proceeds from the February

Offering and August Offering of $1,950, an investment of $37 by a joint venture partner, and from the margin line of credit of $345,

offset by principal payments of notes payable of $36, a change in contingent consideration liability of $164, and by principal payment

on financing lease liability of $53.

Net cash used in financing activities for the nine months ended September 30, 2023 was attributable

to the proceeds from the margin line of credit of $89 thousand and principal payments of notes payable and convertible notes of $4.

September 30, 2024, current assets totaled $4,610 and current liabilities totaled $3,048 as compared to current assets totaling $5,052

and current liabilities totaling $2,549 at December 31, 2023.

As a result, we had working capital of $1,562 at September 30, 2024, compared

to a working capital of $2,503 at December 31, 2023.

The change in the working capital as of September 30, 2024 is primarily attributable

to the loss from operations of $2,713, cash paid for asset acquisition of $400, capital expenditures of $374, offset by net proceeds

of $1,950 from the February Offering and August Offering.

have never declared or paid any cash dividends on our common stock.

For the foreseeable future, we anticipate that all available funds

and any earnings generated in our business will be used to finance the growth of our business and will not be paid out as dividends to

our shareholders.

Any future determination related to our dividend policy will be made at the discretion of our Board of Directors and

will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions,

business prospects and other factors our Board of Directors may deem relevant.

is exploring new product channel sales in consumer products, such as cosmetics, athletic products, and proprietary medical devices.

Company has increased its focus on sales and developing a sales pipeline for potential customers.

This customer base expansion will enable

us to provide financial stability for the foreseeable future, expand our current processes, and position us for long-term shareholder

value creation.

Our recent capital raise expected to close on or about

November 13, 2024 provides working capital necessary to continue our strategic objectives (discussed further within Note 19).

to maintain and attempt to grow our existing contract manufacturing business.

We also plan to continue building and developing our catalogue

of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products.

These products will be target marketed and sold online through social media, television and online marketplaces.

Furthermore, the Company

plans to develop its own proprietary medical devices and explore drug delivery programs for its technology.

Additionally, the Company

continues to evaluate strategic initiatives (e.g., acquisitions) and additional capital raises through debt or equity may be necessary

to achieve these objectives.

expect to continue incurring losses for the near-term future.

Our ability to continue to operate as a going concern in the long term

is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations.

Management may

consider various options to raise capital to fund potential acquisitions through equity or debt offerings.

There can be no assurances,

however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained

on terms satisfactory to us.

The financial statements do not include any adjustments relating to the recoverability and classification

of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern.

Additionally,

it is reasonably possible that estimates made in the financial statements have been, or will be, materially and adversely impacted in

the near term as a result of these conditions, including the recoverability of long-lived assets.

Balance Sheet Arrangements

of September 30, 2024, we had no off-balance sheet arrangements in the nature of guarantee contracts, retained or contingent interests

in assets transferred to entities (or similar arrangements serving as credit, liquidity or market risk support to entities for any such

assets), or obligations (including contingent obligations) arising out of variable interests in entities providing financing, liquidity,

market risk or credit risk support to us, or that engage in leasing, hedging or research and development services with us.

Accounting Policies and Estimates

preparation of our accompanying condensed consolidated financial statements in accordance with generally accepted accounting principles

is based on the selection and application of accounting policies that require us to make significant estimates and assumptions about

the effects of matters that are inherently uncertain.

We consider the accounting policies discussed below to be critical to the understanding

of our Financial Statements.

Actual results could differ from our estimates and assumptions, and any such differences could be material

to our Financial Statements.

compensation – We utilize share-based compensation in the form of incentive stock options.

The fair values of incentive stock

option award grants are estimated as of the date of grant using a Black-Scholes option valuation model.

Compensation expense is recognized

in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required

to obtain full vesting.

The expected term of the awards granted is estimated using the simplified method which computes the expected

term as the sum of the award’s vesting term plus the original contractual term divided by two.

Liability – Warrants to purchase common stock were issued in connection with equity financing raises which occurred during

2019 through 2024.

The fair values of the warrants are estimated as of the date of issuance and again at each year end using a Black-Scholes

option valuation model.

At issuance, the fair value of the warrant is recognized as an equity issuance cost within additional paid-in-capital.

Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations.

term of the awards granted are based on either the three-year or five-year contractual expiration date.

Scholes Inputs - The fair value of each stock option award and warrant issued was estimated on the date of grant using a Black-Scholes

option-valuation model, which requires management to make certain assumptions regarding:

(i) fair value of the common stock that underlies

the stock option;

(ii) the expected volatility in the market price of our common stock;

Compensation and benefits

Share-based compensation

Depreciation and amortization

Advertising, marketing, and Amazon fees

Investor and shareholder services

Franchise tax and corporate insurance

Professional and consulting fees

Other expenses and professional fees

Total selling, general and administrative expenses

Selling, general and administrative expenses increased

by $935, or 90.9%, to $1,964 for the three months ended March 31, 2025, as compared to $1,029 for the three months ended March 31, 2024.

The increase in Selling, general and administrative expenses is primarily attributable to the factors described below.

Compensation and benefits increased by $103, or 40.9%,

to $355 for the three months ended March 31, 2025, as compared to $252 for the three months ended March 31, 2024.

The number of employees

increased compared to the prior period and officer compensation increased in conjunction with contract renewals.

Share-based compensation increased by $110, or 215.7%,

to $161 for the three months ended March 31, 2025, as compared to $51 for the three months ended March 31, 2024.

The share-based compensation

increase is related to the issuance of stock options and restricted awards to our officers, employees, and advisors compared to the same

prior year period.

Advertising, marketing, Amazon fees increased by $505,

or 371.3%, to $641 for the three months ended March 31, 2025, as compared to $136 for the three months ended March 31, 2024.

primarily pertains to an increase in consumer branded product sales year over year.

Investor and shareholder services increased by $1,

or 1.6%, to $63 for the three months ended March 31, 2025, as compared to $62 for the three months ended March 31, 2024.

is due to a reduction of investor services compared to the prior year period.

Franchise taxes and corporate insurance decreased

by $29, or 50.0%, to $29 for the three months ended March 31, 2025, as compared to $58 thousand for the three months ended March 31, 2024.

Professional and consulting fees increased by $142,

or 39.0%, to $506 for the three months ended March 31, 2025, as compared to $364 for the three months ended March 31, 2024.

to incur accounting and consulting fees associated with public company governance requirements.

Additionally, we incurred significant

expenses related to our European Medical Device Regulation project in preparation for entering European markets.

Other Expenses increased by $92, or 122.6%, to $167

for the three months ended March 31, 2025 from $75 for the three months ended March 31, 2024.

Other Selling, general and administrative

expenses generally consist of costs associated with our selling efforts and general management, including information technology, travel,

training and recruiting.

Research and development expenses .

and development expenses were $1 and $2 for the three months ended March 31, 2025 and March 31, 2024, respectively.

Liquidity and Capital Resources ($ in thousands)

Cash Flow (in thousands)

Net cash used in operating activities

Net cash provided by (used in) investing activities

Net cash provided by (used in) financing activities

Net increase (decrease) in cash and cash equivalents

Cash and cash equivalents at beginning of year

Cash and cash equivalent at end of quarter

As of March 31, 2025, we had $1,192 of cash and

cash equivalents , compared to $1,807 of cash and cash equivalents at December 31, 2024.

Net cash used in operating activities was

$400 and $1,092 for the three months ended March 31, 2025 and 2024, respectively.

Net cash used in investing activities was $0 and net

cash used in investing activities was $118 for the three months ended March 31, 2025 and 2024, respectively, consisting

of the sales of marketable securities of $34 and purchases of capital equipment of $152 for three months ended March 31, 2024.

Net cash used in financing activities for March 31,

2025 was $37 is attributable to the principal payments of notes payable and principal payments of financing lease liabilities and payment

of contingent consideration of $178.

Net cash provided by financing activities for the three months ended March 31, 2024 was $929 consisting

of net proceeds from the RDO of $946, offset by principal payments of notes payable of $8 and by principal payment on financing lease

liability of $9.

At March 31, 2025, current assets totaled $4,740 and

current liabilities totaled $2,519, as compared to current assets totaling $5,114 and current liabilities totaling $2,470 at December

As a result, we had working capital of $2,221 at March 31, 2025, compared to a working capital of $2,644 at December

The change in the working capital as of March 31, 2025 is primarily attributable to the loss from operations of $777.

We have never declared or paid any cash dividends

on our common stock.

For the foreseeable future, we anticipate that all available funds and any earnings generated in our business will

be used to finance the growth of our business and will not be paid out as dividends to our shareholders.

Any future determination related

to our dividend policy will be made at the discretion of our Board of Directors and will depend upon, among other factors, our results

of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our Board of

Directors may deem relevant.

Management is exploring new product channel sales

in consumer products, such as cosmetics, athletic products, and proprietary medical devices.

The Company has increased its focus on sales

and developing a sales pipeline for potential customers.

This customer base expansion will enable us to provide financial stability for

the foreseeable future, expand our current processes, and position us for long-term shareholder value creation.

We intend to maintain and attempt to grow our existing

contract manufacturing business.

We also plan to continue building and developing our catalogue of consumer products for sale to branding

partners and to use our in-house capabilities to create and test market additional branded products.

These products will be target marketed

and sold online through social media, television and online marketplaces.

Furthermore, the Company plans to develop its own proprietary

medical devices and explore drug delivery programs for its technology.

Additionally, the Company continues to evaluate strategic initiatives

(e.g., acquisitions) and additional capital raises through debt or equity may be necessary to achieve these objectives.

We expect to continue incurring losses for the near-term

Our ability to continue to operate as a going concern in the long term is dependent upon our ability to manage and grow our current

products and to ultimately achieve profitable operations.

Management may consider various options to raise capital to fund potential acquisitions

through equity or debt offerings.

There can be no assurances, however, that management will be able to obtain sufficient additional funds,

if needed, or that such funds, if available, will be obtained on terms satisfactory to us.

The financial statements do not include any

adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be

unable to continue as a going concern.

Additionally, it is reasonably possible that estimates

made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions,

including the recoverability of long-lived assets.

Off Balance Sheet Arrangements

As of March 31, 2025, we had no off-balance sheet

arrangements in the nature of guarantee contracts, retained or contingent interests in assets transferred to entities (or similar arrangements

serving as credit, liquidity or market risk support to entities for any such assets), or obligations (including contingent obligations)

arising out of variable interests in entities providing financing, liquidity, market risk or credit risk support to us, or that engage

in leasing, hedging or research and development services with us.

Critical Accounting Policies and Estimates

The preparation of our accompanying condensed consolidated

financial statements in accordance with generally accepted accounting principles is based on the selection and application of accounting

policies that require us to make significant estimates and assumptions about the effects of matters that are inherently uncertain.

consider the accounting policies discussed below to be critical to the understanding of our Financial Statements.

Actual results could

differ from our estimates and assumptions, and any such differences could be material to our Financial Statements.

Share-based compensation – We utilize

share-based compensation in the form of incentive stock options.

The fair values of incentive stock option award grants are estimated

as of the date of grant using a Black-Scholes option valuation model.

Compensation expense is recognized in the statements of operations

on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting.

expected term of the awards granted is estimated using the simplified method which computes the expected term as the sum of the award’s

vesting term plus the original contractual term divided by two.

Warrant Liability – Warrants to purchase

common stock were issued in connection with equity financing raises which occurred during 2019 through 2024.

The fair values of the warrants

are estimated as of the date of issuance and again at each year end using a Black-Scholes option valuation model.

At issuance, the fair

value of the warrant is recognized as an equity issuance cost within additional paid-in-capital.

Fair value adjustments to the warrant

liability are recognized in other income (expense) in the statements of operations.

The expected term of the awards granted are based

on either the three-year or five-year contractual expiration date.

Black Scholes Inputs - The fair value of each

stock option award and warrant issued was estimated on the date of grant using a Black-Scholes option-valuation model, which requires

management to make certain assumptions regarding:

(i) fair value of the common stock that underlies the stock option;

(ii) the expected

volatility in the market price of our common stock;

(iii) dividend yield;

(iv) risk-free interest

and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected term).

the Black-Scholes option-valuation model, entities typically estimate the expected volatility based on historical volatilities of the

entity’s own common stock.

Based on the lack of historical data of volatility for the Company’s common stock, the Company

based its estimate of expected volatility on a weighted average of the historical volatility of comparable public companies that manufacture

similar products and are similar in size, stage of life cycle, and financial leverage.

The fair value of the common stock that underlies

the stock option is estimated by the Company considering the price of the most recent issuance of the Company’s common stock.

dividend yield is based upon the assumption that the Company will not declare a dividend over the life of the options.

The risk-free

interest rate is based on the U.S.

Treasury yield curve in effect at the time of grant for bonds with maturities consistent with the

expected term of the related award.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

(iv) risk-free interest rates;

and (iv) the period of time employees

are expected to hold the award prior to exercise (referred to as the expected term).

Under the Black-Scholes option-valuation model, entities

typically estimate the expected volatility based on historical volatilities of the entity’s own common stock.

Based on the lack

of historical data of volatility for the Company’s common stock, the Company based its estimate of expected volatility on a weighted

average of the historical volatility of comparable public companies that manufacture similar products and are similar in size, stage of

life cycle, and financial leverage.

The fair value of the common stock that underlies the stock option is estimated by the Company considering

the price of the most recent issuance of the Company’s common stock.

The dividend yield is based upon the assumption that the Company

will not declare a dividend over the life of the options.

The risk-free interest rate is based on the U.S.

Treasury yield curve in effect

at the time of grant for bonds with maturities consistent with the expected term of the related award.

QUANTITATIVE AND QUALITATIVE DISCLOSURES

ABOUT MARKET RISK

Not required.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis